Endogenous intrahepatic IFNs and association with IFN-free HCV Treatment outcome

Journal of Clinical Investigation

Volumn 124, Issue 8, 2014, Pages 3352-3363

  Meissner, Eric G ^a   Wu, David ^a   Osinusi, Anu ^a,b   Bon, Dimitra ^c   Virtaneva, Kimmo ^d   Sturdevant, Dan ^d   Porcella, Steve ^d   Wang, Honghui ^e   Herrmann, Eva ^c   McHutchison, John ^f   Suffredini, Anthony F ^e   Polis, Michael ^a   Hewitt, Stephen ^g   Prokunina Olsson, Ludmila ^g   Masur, Henry ^e   Fauci, Anthony S ^a   Kottilil, Shyamasundaran ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c GOETHE UNIVERSITY   (Germany)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f GILEAD SCIENCES   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; MESSENGER RNA; RIBAVIRIN; SOFOSBUVIR; 2-((5-(2,4-DIOXO-3,4-DIHYDRO-2H-PYRIMIDIN-1-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YLMETHOXY)PHENOXYPHOSPHORYLAMINO)PROPIONIC ACID ISOPROPYL ESTER; ALPHA INTERFERON; ANTIVIRUS AGENT; CXCL10 PROTEIN, HUMAN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IFNA2 PROTEIN, HUMAN; IFNL4 PROTEIN, HUMAN; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; PROTEINASE; URIDINE PHOSPHATE; USP18 PROTEIN, HUMAN;

ARTICLE; GENE EXPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERFERON PRODUCTION; LIVER BIOPSY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL CLEARANCE; ANALOGS AND DERIVATIVES; BLOOD; CLASSIFICATION; CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECTS; GENETICS; HEPATITIS C, CHRONIC; IMMUNOLOGY; LIVER; METABOLISM; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE;

ANTIVIRAL AGENTS; CHEMOKINE CXCL10; DRUG THERAPY, COMBINATION; ENDOPEPTIDASES; GENE EXPRESSION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERFERONS; INTERLEUKINS; LIVER; RECURRENCE; RIBAVIRIN; RNA, MESSENGER; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE;

EID: 84905492815     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI75938     Document Type: Article

References (50)

1. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013;368(20):1907-1917.
2. Casey LC, Lee WM. Hepatitis C virus therapy update 2013. Curr Opin Gastroenterol. 2013;29(3):243-249.
3. Shah N, Pierce T, Kowdley KV. Review of directacting antiviral agents for the treatment of chronic hepatitis C. Expert Opin Investig Drugs. 2013;22(9):1107-1121.
4. Kowdley KV, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatmentnaive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013;381(9883):2100-2107.
5. Jacobson IM, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867-1877.
6. Lawitz E, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878-1887.
7. Gane EJ, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. Engl J Med. 2013;368(1):34-44.
8. Osinusi A, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013;310(8):804-811.
9. Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med. 2013;19(7):859-868.
10. Rosen HR. Emerging concepts in immunity to hepatitis C virus infection. J Clin Invest. 2013;123(10):4121-4130.
11. Heim MH. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol. 2013;13(7):535-542.
12. Donnelly RP, Dickensheets H, O'Brien TR. Interferon-lambda and therapy for chronic hepatitis C virus infection. Trends Immunol. 2011;32(9):443-450.
13. Wieland S, et al. Simultaneous detection of hepatitis C virus interferon stimulated gene expression in infected human liver. Hepatology. 2014;59(6):2121-2130.
14. Lau DT, et al. Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroenterology. 2013;144(2):402-413.
15. McGilvray I, et al. Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology. 2012;142(5):1122-1131.
16. Sarasin-Filipowicz M, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A. 2008;105(19):7034-7039.
17. Feld JJ, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology. 2007;46(5):1548-1563.
18. Rusinova I, et al. Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res. 2013;41(Database issue):D1040-D1046.
19. Marcello T, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006;131(6):1887-1898.
20. Wilkins C, et al. IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology. 2013;57(2):461-469.
21. Metz P, et al. Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication. Hepatology. 2012;56(6):2082-2093.
22. Dill MT, et al. Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. Gastroenterology. 2012;143(3):777-786.
23. Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol. 2011;89(2):207-215.
24. Diamond DL, et al. Proteome and computational analyses reveal new insights into the mechanisms of hepatitis C virus-mediated liver disease posttransplantation. Hepatology. 2012;56(1):28-38.
25. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18(7):1028-1040.
26. Thomas E, et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology. 2012;142(4):978-988.
27. Diegelmann J, et al. Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS One. 2010;5(12):e15200.
28. Honda M, et al. Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes. Hepatology. 2014;59(3):828-838.
29. Ge D, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399-401.
30. Thomas DL, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798-801.
31. Prokunina-Olsson L, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45(2):164-171.
32. Meissner EG, Bon D, Prokunina-Olsson L, Tang W, Masur H, O'Brien TR, Herrmann E, Kottilil S, Osinusi A. IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis. 2014;209(11):1700-1704.
33. McFarland AP, et al. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol. 2014;15(1):72-79.
34. Aka PV, et al. Association of the IFNL4-ΔG allele with impaired spontaneous clearance of hepatitis C virus. J Infect Dis. 2014;209(3):350-354.
35. Buckley CD, Gilroy DW, Serhan CN, Stockinger B, Tak PP. The resolution of inflammation. Nat Rev Immunol. 2013;13(1):59-66.
36. Testoni B, Levrero M, Durantel D. Mechanism of action of ribavirin in anti-HCV regimens: new insights for an age-old question? Gut. 2014;63(1):3-4.
37. Feld JJ, et al. Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology. 2010;139(1):154-162.
38. Stevenson NJ, Murphy AG, Bourke NM, Keogh CA, Hegarty JE, O'Farrelly C. Ribavirin enhances IFN-α signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV. PLoS One. 2011;6(11):e27866.
39. Makowska Z, Duong FH, Trincucci G, Tough DF, Heim MH. Interferon-β and interferon-κ signaling is not affected by interferon-induced refractoriness to interferon-α in vivo. Hepatology. 2011;53(4):1154-1163.
40. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14(1):36-49.
41. Zhang S, Saha B, Kodys K, Szabo G. IFN-γ production by human natural killer cells in response to HCV-infected hepatoma cells is dependent on accessory cells. J Hepatol. 2013;59(3):442-449.
42. Zhang S, Kodys K, Li K, Szabo G. Human type 2 myeloid dendritic cells produce interferon-κ and amplify interferon-α in response to hepatitis C virus infection. Gastroenterology. 2013;144(2):414-425.
43. Jenne CN, Kubes P. Immune surveillance by the liver. Nat Immunol. 2013;14(10):996-1006.
44. Sheahan T, et al. Interferon κ alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe. 2014;15(2):190-202.
45. Amanzada A, Kopp W, Spengler U, Ramadori G, Mihm S. Interferon-κ4 (IFNL4) transcript expression in human liver tissue samples. PLoS One. 2013;8(12):e84026.
46. Holmes JA, Desmond PV, Thompson AJ. Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection? J Viral Hepat. 2012;19(10):677-684.
47. Ishak K, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22(6):696-699.
48. Knodell RG, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1(5):431-435.
49. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Stat Methodol. 1995;57(1):289-300.
50. Wang F, et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffinembedded tissues. J Mol Diagn. 2012;14(1):22-29.